Current antiplatelet agents, new inhibitors and therapeutic targets
© 2020 médecine/sciences – Inserm..
Cardiovascular diseases are the leading cause of deaths in the world. Platelets play a major role in the occurrence of these diseases and the development of antiplatelet drugs is a priority in the fight against cardiovascular diseases-associated mortality. Aspirin and thienopyridine-based P2Y12 inhibitors are the main drugs currently used. These molecules target the initiation of platelets activation and are responsible for a moderate inhibitory action. Other antiplatelet agents, as glycoprotein (GP) IIb/IIIa antagonists, inhibit platelet aggregation independently of initial activation-associated pathways, but are responsible for increased hemorrhagic events. Regarding each antiplatelet agent's specific characteristics, the prescription of these drugs must take into account the type of cardiovascular event, the age of the patient, the past medical history, and the potential hemorrhagic adverse events. Thus, there is a need for the development of new molecules with a more targeted effect, maintaining optimal efficiency but with a reduction of the hemorrhagic risk, which is the principal limitation of these treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Medecine sciences : M/S - 36(2020), 4 vom: 01. Apr., Seite 348-357 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Antiplaquettaires actuels, en cours de développement et cibles thérapeutiques |
|---|
| Beteiligte Personen: |
El Alaoui, Mustapha Zine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aspirin |
|---|
| Anmerkungen: |
Date Completed 01.10.2020 Date Revised 14.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1051/medsci/2020061 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309403855 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309403855 | ||
| 003 | DE-627 | ||
| 005 | 20231225133832.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1051/medsci/2020061 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM309403855 | ||
| 035 | |a (NLM)32356711 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a El Alaoui, Mustapha Zine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current antiplatelet agents, new inhibitors and therapeutic targets |
| 246 | 3 | 3 | |a Antiplaquettaires actuels, en cours de développement et cibles thérapeutiques |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.10.2020 | ||
| 500 | |a Date Revised 14.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 médecine/sciences – Inserm. | ||
| 520 | |a Cardiovascular diseases are the leading cause of deaths in the world. Platelets play a major role in the occurrence of these diseases and the development of antiplatelet drugs is a priority in the fight against cardiovascular diseases-associated mortality. Aspirin and thienopyridine-based P2Y12 inhibitors are the main drugs currently used. These molecules target the initiation of platelets activation and are responsible for a moderate inhibitory action. Other antiplatelet agents, as glycoprotein (GP) IIb/IIIa antagonists, inhibit platelet aggregation independently of initial activation-associated pathways, but are responsible for increased hemorrhagic events. Regarding each antiplatelet agent's specific characteristics, the prescription of these drugs must take into account the type of cardiovascular event, the age of the patient, the past medical history, and the potential hemorrhagic adverse events. Thus, there is a need for the development of new molecules with a more targeted effect, maintaining optimal efficiency but with a reduction of the hemorrhagic risk, which is the principal limitation of these treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Platelet Glycoprotein GPIIb-IIIa Complex |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 700 | 1 | |a Guy, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Khalki, Loubna |e verfasserin |4 aut | |
| 700 | 1 | |a Limami, Youness |e verfasserin |4 aut | |
| 700 | 1 | |a Benomar, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Zaid, Nabil |e verfasserin |4 aut | |
| 700 | 1 | |a Cherrah, Yahia |e verfasserin |4 aut | |
| 700 | 1 | |a Mekhfi, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Cadi, Rachida |e verfasserin |4 aut | |
| 700 | 1 | |a Zaid, Younes |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medecine sciences : M/S |d 1996 |g 36(2020), 4 vom: 01. Apr., Seite 348-357 |w (DE-627)NLM08683102X |x 1958-5381 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2020 |g number:4 |g day:01 |g month:04 |g pages:348-357 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1051/medsci/2020061 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2020 |e 4 |b 01 |c 04 |h 348-357 | ||